1
|
Maleki B, Haghshenas N, Rezaei-Tavirani M, Ahmadzadeh A, Abolghazi A, Robati RM. Global Prevalence of Human Demodex Mite: A Systematic Review and Meta-Analysis. Acta Trop 2025:107693. [PMID: 40513697 DOI: 10.1016/j.actatropica.2025.107693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2025] [Revised: 06/02/2025] [Accepted: 06/10/2025] [Indexed: 06/16/2025]
Abstract
Demodex mites are common ectoparasites in humans that typically reside as commensals in sebaceous glands, but under certain host conditions, they may become opportunistic pathogens. Despite numerous localized studies on the prevalence of human Demodex mites, the global prevalence and associated risk factors remain unclear. This study aims to systematically assess the global prevalence of human Demodex mites and the effects of age, gender, facial sampling region, humidity, World Health Organization (WHO) regions and countries, and population factors on this prevalence. A systematic literature search, following PRISMA guidelines, was conducted in multiple databases from January 2000 to January 2025. Meta-analysis using a random-effects model estimated the global prevalence of Demodex mites and examined associations with demographic, geographic, and climatic factors. Meta-regression, sensitivity analysis, and Egger's test were conducted to assess publication bias and the robustness of the findings. The global pooled prevalence of human Demodex mites was approximately 35% (based on available studies), with the highest prevalence observed in the South-East Asia Region (SEARO) at 44%. The highest prevalence among age groups was found in older adults (>60 years), reaching 59%, while the highest facial region-specific prevalence was observed in the eyelashes at 33%. Among different population groups, ophthalmology patients showed the highest prevalence (57%). Additionally, the prevalence was slightly higher in females compared to males. The analysis revealed significant heterogeneity and publication bias. The sensitivity analysis confirmed the stability of the prevalence estimate. Meta-regression identified significant differences in sample size but no associations with humidity or publication year. This meta-analysis highlights a global prevalence of human Demodex mites, especially among older adults and ophthalmology patients, emphasizing the need for clinical awareness and further studies.
Collapse
Affiliation(s)
- Bahman Maleki
- Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Mostafa Rezaei-Tavirani
- Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Alireza Ahmadzadeh
- Department of Lab Sciences, School of Allied Medical Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Ahmad Abolghazi
- Department of Medical Parasitology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Reza M Robati
- Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
5
|
Rhee MK, Yeu E, Barnett M, Rapuano CJ, Dhaliwal DK, Nichols KK, Karpecki P, Mah FS, Chan A, Mun J, Gaddie IB. Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. Eye Contact Lens 2023; 49:311-318. [PMID: 37272680 PMCID: PMC10351901 DOI: 10.1097/icl.0000000000001003] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/11/2023] [Indexed: 06/06/2023]
Abstract
ABSTRACT Demodex blepharitis is a common disease of the eyelid, affecting approximately 25 million Americans. This article reviews what is known about the mechanisms and impact of Demodex blepharitis, risk factors, signs and symptoms, diagnostic techniques, current management options, and emerging treatments. Demodex mites contribute to blepharitis in several ways: direct mechanical damage, as a vector for bacteria, and by inducing hypersensitivity and inflammation. Risk factors for Demodex blepharitis include increasing age, rosacea, and diabetes. The costs, symptom burden, and psychosocial effects of Demodex blepharitis are considerable. The presence of collarettes is pathognomonic for Demodex blepharitis. Redness, dryness, discomfort, foreign body sensation, lash anomalies, and itching are also hallmarks of the disease. Although a number of oral, topical, eyelid hygiene and device-based options have been used clinically and evaluated in studies for the management of Demodex blepharitis, none have been FDA approved to treat the disease. Recent randomized controlled clinical trials suggest that lotilaner ophthalmic solution, 0.25%, is a topical treatment with the potential to eradicate Demodex mites and eliminate collarettes and eyelid redness for an extended period.
Collapse
Affiliation(s)
- Michelle K. Rhee
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Elizabeth Yeu
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Melissa Barnett
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Christopher J. Rapuano
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Deepinder K. Dhaliwal
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Kelly K. Nichols
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Paul Karpecki
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Francis S. Mah
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Arthur Chan
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - James Mun
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| | - Ian Benjamin Gaddie
- Department of Ophthalmology (M.K.R.), Icahn School of Medicine, Mt. Sinai, NY; Virginia Eye Consultants (E.Y.), Norfolk, VA; University of California (M.B.), Davis Eye Center, Sacramento, CA; Sidney Kimmel Medical College at Thomas Jefferson University (C.J.R.), Philadelphia, PA; University of Pittsburgh School of Medicine (D.K.D.), Pittsburgh, PA; University of Alabama at Birmingham School of Optometry (K.K.N.), Birmingham, AL; Kentucky College of Optometry (P.K.), University of Pikeville, Pikeville, KY; Kentucky Eye Institute (P.K.), Lexington, KY; Scripps Clinic Medical Group (F.S.M.), La Jolla, CA; Tarsus Pharmaceuticals (A.C., J.M.), Irvine, CA; and Gaddie Eye Centers (I.B.G.), Louisville, KY
| |
Collapse
|